Drugmaker Baxalta is working with bankers to buy a U.S.-based hematology and oncology specialist valued at about $2 billion.» Read More
A wash of earnings news and weekly jobless claims will help decide the market's course Thursday, but there's a good chance there will be follow through to Wednesday's rally.
Pharmaceutical stocks were winners today on the earnings front, and CNBC guests say they can be winners on the portfolio front as well.
J.P. Morgan analysts today though came up with some names, in a note titled "The Franchise 16 - Stocks to own beyond the market turmoil." They see these as core investments for the next 12 to 18 months.
The Dow fell Tuesday as Congress spent the day bickering over the Wall Street bailout. Also, after hours we learned Warren Buffett is buying Goldman shares.
Twice each year, Standard and Poor's runs a stock screen, designed to find stocks that Warren Buffett might find attractive based on his general investment philosophy. The new list has just been released. Guess what well-known name is missing this time around. (Pay no attention to the picture on the left.)
Baxter researchers unveiled positive mid-stage test results on an intravenous drug, Wednesday, which is already in late-stage development in a very small number of patients.
To help investors prepare their portfolios before the weekend, CNBC asked the experts for their best trades now.
Ed Sheidlower is avoiding financials. But the Bryce Capital Management portfolio manager sees other sectors -- and stocks -- as good investments.
To give investors an edge, CNBC asked the experts for their best stock picks now.
You’ve gotta’ love modern medicine. Not only does it cure stomach upset now it may be the best remedy for what ails your portfolio.
With our economy struggling under the weight of multiple potential large bank failures, with high oil prices, high food prices—you name it—financially strangling indiviuals and companies alike, you need the Cramerican Marine Field Guide to recessions if you want to try and make money in this market.
German health care group Fresenius plans to buy APP Pharmaceuticals in a $3.7 billion deal to expand into the North American intravenous generic drugs market.
Almost everywhere they looked during the week, investors saw red ink flowing. But CNBC guests worked hard to find bright spots in the murk.
To give investors an edge, CNBC asked the market experts for their best stock picks now.
Shares of many health-care companies have been hit hard this year. But Schwab's Paul Alan Davis says there are some promising opportunities.
"Health care" is two words -- and the health care sector is increasingly being viewed as two very different sectors: pharmaceuticals and managed care, which are in trouble; and medical devices and services, which are not. Paul Alan Davis of Charles Schwab Investment Management offered advice for playing the sector(s).
Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.
Goldman Sachs analysts say stock investors should look to larger cap and defensive sectors as a way to play the uncertainty of presidential primary season. While they say the major party nominees should become clear by "Super Duper Tuesday," there is greater electoral and policy uncertainty in this Presidential race because there are no incumbents running.
What's the difference between a best of breed medical stock and one that's worst of breed? Let Cramer explain it to you.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Today Cramer talks drilling stocks, MasterCard, Sprint and many, many more...